Latest & greatest articles for obesity

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on obesity or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on obesity and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for obesity

101. Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities.

Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities. Importance: The association of bariatric surgery and specialized medical obesity treatment with beneficial and detrimental outcomes remains uncertain. Objective: To compare changes in obesity-related comorbidities in patients with severe obesity (body mass index ≥40 or ≥35 and at least 1 comorbidity) undergoing bariatric surgery or specialized medical treatment (...) . Design, Setting, and Participants: Cohort study with baseline data of exposures from November 2005 through July 2010 and follow-up data from 2006 until death or through December 2015 at a tertiary care outpatient center, Vestfold Hospital Trust, Norway. Consecutive treatment-seeking adult patients (n = 2109) with severe obesity assessed (221 patients excluded and 1888 patients included). Exposures: Bariatric surgery (n = 932, 92% gastric bypass) or specialized medical treatment (n = 956) including

JAMA2018 Full Text: Link to full Text with Trip Pro

102. Clinic and Home-Based Behavioral Intervention for Obesity in Preschoolers: A Randomized Trial

Clinic and Home-Based Behavioral Intervention for Obesity in Preschoolers: A Randomized Trial 29150147 2017 12 26 2017 12 26 1097-6833 192 2018 Jan The Journal of pediatrics J. Pediatr. Clinic and Home-Based Behavioral Intervention for Obesity in Preschoolers: A Randomized Trial. 115-121.e1 S0022-3476(17)31317-3 10.1016/j.jpeds.2017.09.063 To test the hypotheses that an innovative skills-based behavioral family clinic and home-based intervention (LAUNCH) would reduce body mass index z score (...) (BMIz) compared with motivational interviewing and to standard care in preschool-aged children with obesity. Randomized controlled trial with children between the ages of 2 and 5 years above the 95th percentile for body mass index for age and sex recruited from 27 pediatrician offices across 10 recruitment cycles between March 12, 2012 and June 8, 2015. Children were randomized to LAUNCH (an 18-session clinic and home-based behavioral intervention), motivational interviewing (delivered at the same

EvidenceUpdates2018

103. Dose, Content, and Mediators of Family-Based Treatment for Childhood Obesity: A Multisite Randomized Clinical Trial

Dose, Content, and Mediators of Family-Based Treatment for Childhood Obesity: A Multisite Randomized Clinical Trial 29084318 2017 12 12 2018 01 09 2168-6211 171 12 2017 Dec 01 JAMA pediatrics JAMA Pediatr Dose, Content, and Mediators of Family-Based Treatment for Childhood Obesity: A Multisite Randomized Clinical Trial. 1151-1159 10.1001/jamapediatrics.2017.2960 Elucidation of optimal dosing and treatment content is critical for health care providers, payers, and policy makers, as well (...) as mechanisms of change to inform intervention delivery and training initiatives for childhood obesity. To evaluate effects, following a 4-month family-based behavioral weight loss treatment (FBT), of 2 doses (HIGH or LOW) of a weight-control intervention (enhanced social facilitation maintenance [SFM+]) vs a weight-control education condition (CONTROL; matched for dose with LOW), on child anthropometrics, and to explore putative mediators of weight loss outcomes. For this parallel-group

EvidenceUpdates2018

104. Cluster randomised controlled trial and economic and process evaluation to determine the effectiveness and cost effectiveness of a novel intervention [Healthy Lifestyles Programme (HeLP)] to prevent obesity in school children

Cluster randomised controlled trial and economic and process evaluation to determine the effectiveness and cost effectiveness of a novel intervention [Healthy Lifestyles Programme (HeLP)] to prevent obesity in school children Cluster randomised controlled trial and economic and process evaluation to determine the effectiveness and cost effectiveness of a novel intervention [Healthy Lifestyles Programme (HeLP)] to prevent obesity in school children Journals Library An error occurred retrieving (...) content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} The novel school-located Healthy Lifestyles Programme did not prevent obesity in 9-10 year olds at two year follow up. {{author}} {{($index

NIHR HTA programme2018

105. Obesity in children

Obesity in children Obesity in children - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Obesity in children Last reviewed: August 2018 Last updated: February 2018 Summary Behavioural and environmental factors are primarily responsible for the dramatic increase in obesity in the past 2 decades, although genes play an important role in regulation of body weight. Calculating body mass index (BMI) is the most widely (...) accepted method of screening for obesity in children. Abnormal BMI cut-offs in children are determined by age- and gender-specific percentiles. The dramatic increase in childhood obesity has led to a marked increase in the diagnosis of impaired glucose tolerance and type 2 diabetes mellitus in children. Preventing excessive weight gain in children is of paramount importance in confronting the obesity epidemic, as obesity is difficult to treat at all ages, and obese children tend to become obese adults

BMJ Best Practice2018

106. Obesity in adults

Obesity in adults Obesity in adults - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Obesity in adults Last reviewed: August 2018 Last updated: January 2018 Summary Presentation of obesity may range from asymptomatic to presentation complicated by multiple comorbidities, including cancer, CAD, diabetes, hypertension, gout, obstructive sleep apnoea, and osteoarthritis. The definitive test for the diagnosis of obesity (...) remains the BMI (obesity is defined as a BMI ≥30 kg/m^2). Central or abdominal obesity has a stronger association with obesity-related comorbidity than peripheral (i.e., subcutaneous) obesity, so waist circumference may be a better indicator of the risk for obesity-related comorbidity than BMI. The mainstay of non-surgical treatment of obesity is diet and exercise, with psychological therapy as a recommended adjunct for all patients. The risk of complications is low, but the overall efficacy

BMJ Best Practice2018

108. Impact of Misclassification of Obesity by Body Mass Index on Mortality in Patients With CKD

Impact of Misclassification of Obesity by Body Mass Index on Mortality in Patients With CKD Redirecting

Kidney international reports2017 Full Text: Link to full Text with Trip Pro

109. Intragastric Balloon for Obesity Treatment: Safety, Tolerance, and Efficacy

Intragastric Balloon for Obesity Treatment: Safety, Tolerance, and Efficacy E-Mail karger@karger.com Original Article GE Port J Gastroenterol 2018;25:236–242 DOI: 10.1159/000485428 Intragastric Balloon for Obesity Treatment: Safety, Tolerance, and Efficacy Joana Ribeiro da Silva Luísa Proença Adélia Rodrigues Rolando Pinho Ana Ponte Jaime Rodrigues Mafalda Sousa Rita Almeida João Carvalho Department of Gastroenterology, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal (...) or obese in- dividuals, a WL that was =10% of weight at baseline was achieved in 54.3% and sustained at 6–12 months in 41.4% of participants. IGBs are an attractive intermediate option be- tween diet and exercise programs and bariatric surgery. In general, IGB placement is a safe and well-tolerated proce- dure. © 2017 Sociedade Portuguesa de Gastrenterologia Published by S. Karger AG, Basel Balão Intragástrico no Tratamento da Obesidade: Segurança, Tolerância e Eficácia Palavras Chave Balão

GE Portuguese journal of gastroenterology2017 Full Text: Link to full Text with Trip Pro

110. Walkable neighborhoods and obesity: Evaluating effects with a propensity score approach

Walkable neighborhoods and obesity: Evaluating effects with a propensity score approach Redirecting

SSM - population health2017 Full Text: Link to full Text with Trip Pro

112. A Medically Supervised Pregnancy Exercise Intervention in Obese Women: A Randomized Controlled Trial

A Medically Supervised Pregnancy Exercise Intervention in Obese Women: A Randomized Controlled Trial 29016485 2017 11 02 2017 11 02 1873-233X 130 5 2017 Nov Obstetrics and gynecology Obstet Gynecol A Medically Supervised Pregnancy Exercise Intervention in Obese Women: A Randomized Controlled Trial. 1001-1010 10.1097/AOG.0000000000002267 To evaluate whether an intensive, medically supervised exercise intervention improved maternal glycemia and gestational weight gain in obese pregnant women when (...) with 93.6±7.2 mg/dL (n=43) (P=.13) or in the incidence of gestational diabetes mellitus at 24-28 weeks of gestation: 48.8% (n=21/43) compared with 58.1% (n=25/43) (P=.51) in the control and exercise groups, respectively. At 36 weeks of gestation, excessive gestational weight gain greater than 9.1 kg was lower in the exercise group, 23.5% compared with 45.2% in the control group (P<.05). An intensive, medically supervised exercise intervention for obese women from early pregnancy did not improve maternal

EvidenceUpdates2017

113. Effects of Bariatric Surgery in Obese Patients With Hypertension: The GATEWAY Randomized Trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension)

Effects of Bariatric Surgery in Obese Patients With Hypertension: The GATEWAY Randomized Trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension) 29133606 2017 11 14 1524-4539 2017 Nov 13 Circulation Circulation Effects of Bariatric Surgery in Obese Patients With Hypertension: The GATEWAY Randomized Trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension). CIRCULATIONAHA.117.032130 10.1161/CIRCULATIONAHA.117.032130 BACKGROUND : Recent research efforts (...) on bariatric surgery have focused on metabolic and diabetes mellitus resolution. Randomized trials designed to assess the impact of bariatric surgery in patients with obesity and hypertension are needed. METHODS : In this randomized, single-center, nonblinded trial, we included patients with hypertension (using ≥2 medications at maximum doses or >2 at moderate doses) and a body mass index between 30.0 and 39.9 kg/m2 Patients were randomized to Roux-en-Y gastric bypass plus medical therapy or medical therapy alone

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

114. Naltrexone?bupropion for managing overweight and obesity

Naltrexone?bupropion for managing overweight and obesity Naltre Naltrex xone–bupropion for managing one–bupropion for managing o ov verweight and obesity erweight and obesity T echnology appraisal guidance Published: 12 December 2017 nice.org.uk/guidance/ta494 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Naltrexone–bupropion for managing overweight and obesity (TA494) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 17Contents Contents 1 Recommendations 4 2 The technology 5 3 Committee discussion 6

National Institute for Health and Clinical Excellence - Technology Appraisals2017

115. Simulation of Growth Trajectories of Childhood Obesity into Adulthood.

Simulation of Growth Trajectories of Childhood Obesity into Adulthood. BACKGROUND: Although the current obesity epidemic has been well documented in children and adults, less is known about long-term risks of adult obesity for a given child at his or her present age and weight. We developed a simulation model to estimate the risk of adult obesity at the age of 35 years for the current population of children in the United States. METHODS: We pooled height and weight data from five nationally (...) representative longitudinal studies totaling 176,720 observations from 41,567 children and adults. We simulated growth trajectories across the life course and adjusted for secular trends. We created 1000 virtual populations of 1 million children through the age of 19 years that were representative of the 2016 population of the United States and projected their trajectories in height and weight up to the age of 35 years. Severe obesity was defined as a body-mass index (BMI, the weight in kilograms divided

NEJM2017

116. Excessive Weight Gain, Obesity, and Cancer: Opportunities for Clinical Intervention

Excessive Weight Gain, Obesity, and Cancer: Opportunities for Clinical Intervention 28973170 2017 12 13 2018 11 28 1538-3598 318 20 2017 Nov 28 JAMA JAMA Excessive Weight Gain, Obesity, and Cancer: Opportunities for Clinical Intervention. 1975-1976 10.1001/jama.2017.15519 Massetti Greta M GM Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia. Dietz William H WH Redstone Global Center for Prevention and Wellness, Milken Institute School (...) Dec;13(12):1063-72 21733057 Obesity (Silver Spring). 2016 Sep;24(9):1983-8 27465909 JAMA. 2018 Jun 19;319(23):2442 29922821 Humans Neoplasms etiology Obesity complications epidemiology Overweight complications epidemiology Prevalence United States epidemiology Weight Gain 2017 10 4 6 0 2017 12 14 6 0 2017 10 4 6 0 ppublish 28973170 2656710 10.1001/jama.2017.15519 PMC5712448 NIHMS910924

JAMA2017 Full Text: Link to full Text with Trip Pro

117. Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK.

Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK. This report contains new and follow-up metric data relating to the eight main recommendations of the Lancet Standing Commission on Liver Disease in the UK, which aim to reduce the unacceptable harmful consequences of excess alcohol consumption, obesity, and viral hepatitis. For alcohol, we provide data on alcohol dependence, damage (...) to families, and the documented increase in alcohol consumption since removal of the above-inflation alcohol duty escalator. Alcoholic liver disease will shortly overtake ischaemic heart disease with regard to years of working life lost. The rising prevalence of overweight and obesity, affecting more than 60% of adults in the UK, is leading to an increasing liver disease burden. Favourable responses by industry to the UK Government's soft drinks industry levy have been seen, but the government cannot

Lancet2017

118. The Perceptions of Medical School Students and Faculty Toward Obesity Medicine Education: Survey and Needs Analysis

The Perceptions of Medical School Students and Faculty Toward Obesity Medicine Education: Survey and Needs Analysis JME-The Perceptions of Medical School Students and Faculty Toward Obesity Medicine Education: Survey and Needs Analysis | Metcalf | JMIR Medical Education Sorry, you need to enable javascript for this page to function properly. Menu Search User Sign Up Follow Us on Twitter Browse Journal Browse By Year Browse by Year: Other Journals Want to publish? Start your next submission (...) in . Copyeditors: No access to RefCheck in Copyediting Steps 1 and 3. Advertisement This paper is in the following e-collection/theme issue: ; ; ; Clinical Tools, Inc., Chapel Hill, NC, United States *these authors contributed equally Corresponding Author Close Corresponding Author: Mary Metcalf, MPH, PhD Clinical Tools, Inc. 101 Market St Chapel Hill, NC, 27516 United States Phone: 1 919 960 8118 Fax:1 8448 5519 Email: ; ; ; ; , ]. Obesity is the second leading cause of preventable death in the United States

JMIR medical education2017 Full Text: Link to full Text with Trip Pro

119. Metabolic Concomitants of Obese and Nonobese Women With Features of Polycystic Ovarian Syndrome

Metabolic Concomitants of Obese and Nonobese Women With Features of Polycystic Ovarian Syndrome 29264465 2018 11 13 2472-1972 1 12 2017 Dec 01 Journal of the Endocrine Society J Endocr Soc Metabolic Concomitants of Obese and Nonobese Women With Features of Polycystic Ovarian Syndrome. 1417-1427 10.1210/js.2017-00323 Polycystic ovarian syndrome (PCOS) is often associated with obesity and diabetes. The present study measured body fat distribution and metabolic risk factors in women with features (...) women. Nonobese PCOS and non-PCOS women had a similar body fat content and distribution, HOMA-IR, and hepatic triglyceride content. Obese PCOS women had a similar total body fat percentage compared with their non-PCOS counterparts (41.4% and 41.4% respectively). Both obese groups had similar intraperitoneal fat (1.4% of total body mass in PCOS vs 1.4% in non-PCOS). However, obese PCOS women had a greater ratio of truncal/lower body fat (1.42 vs 1.27; P < 0.016). They also had greater insulin

Journal of the Endocrine Society2017 Full Text: Link to full Text with Trip Pro

120. Nutrition and Exercise Rehabilitation in Obesity hypoventilation syndrome (NERO): a pilot randomised controlled trial

Nutrition and Exercise Rehabilitation in Obesity hypoventilation syndrome (NERO): a pilot randomised controlled trial 28971973 2017 10 03 2017 10 03 1468-3296 2017 Sep 29 Thorax Thorax Nutrition and Exercise Rehabilitation in Obesity hypoventilation syndrome (NERO): a pilot randomised controlled trial. thoraxjnl-2016-209826 10.1136/thoraxjnl-2016-209826 Respiratory management of obesity hypoventilation syndrome (OHS) focusses on the control of sleep-disordered breathing rather than (...) the treatment of obesity. Currently, there are no data from randomised trials of weight loss targeted rehabilitation programmes for patients with OHS. A 3-month multimodal hybrid inpatient-outpatient motivation, exercise and nutrition rehabilitation programme, in addition to non invasive ventilation (NIV), would result in greater per cent weight loss compared with standard care. A single-centre pilot randomised controlled trial allocated patients to either standard care or standard care plus rehabilitation

EvidenceUpdates2017